Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of endostar on liver cancer through optical molecular imaging

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Zhang, Qian ^a,b   Du, Yang ^b   Xue, Zhenwen ^b   Chi, Chongwei ^b   Jia, Xiaohua ^b   Tian, Jie ^a,b  

^a XIDIAN UNIVERSITY   (China)

^b INSTITUTE OF AUTOMATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; GREEN FLUORESCENT PROTEIN; RECOMBINANT ENDOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE MOLECULAR IMAGING; CANCER CELL CULTURE; CANCER INHIBITION; CANCER LOCALIZATION; CELL LABELING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE MOLECULAR TOMOGRAPHY; HISTOPATHOLOGY; IMAGING AND DISPLAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR IMAGING; MOUSE; NONHUMAN; RELIABILITY; SUBCUTANEOUS TISSUE TUMOR; TREATMENT DURATION; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; BODY WEIGHT; CELL LINE, TUMOR; ENDOSTATINS; FLUORESCENCE; HUMANS; IMAGING, THREE-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; OPTICAL IMAGING; SUBCUTANEOUS TISSUE; TUMOR BURDEN; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896913037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085559     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858. (Pubitemid 46094197)
3. Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16. (Pubitemid 39423365)
4. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
5. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nature medicine 17: 1359-1370.
6. Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880. (Pubitemid 39434320)
7. Tam K (2013) The Roles of Doxorubicin in Hepatocellular Carcinoma. ADMET & DMPK 1: 29-44.
8. Folkman J (2006) Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE DOI: 10.1126/stke.3542006pe35.
9. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
10. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. (Pubitemid 28015876)
11. Ling Y, Lu N, Gao Y, Chen Y, Wang S, et al. (2009) Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res 29: 411-417.
12. Dong X, Zhao X, Xiao T, Tian H, Yun C (2011) Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg 59: 133-136.
13. Xu W, Ye P, Li Z, Shi J, Wang W, et al. (2010) Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells. Molecular Biology 44: 585-590.
14. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Experimental cell research 312: 594-607.
15. Cai W, Gambhir SS, Chen X (2008) Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445: 141-176.
16. Cai W, Chen X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49 Suppl 2: 113S-128S. (Pubitemid 351948040)
17. Willmann JK, Van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nature Reviews Drug Discovery 7: 591-607. (Pubitemid 351927724)
18. Jaffer FA, Libby P, Weissleder R (2009) Optical and multimodality molecular imaging insights into atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 29: 1017-1024.
19. Baker M (2010) Whole-animal imaging: The whole picture. Nature 463: 977-980.
20. Tian J, Bai J, Bao S (2013) Optical Multi-Modality Molecular Imaging. Molecular Imaging: Springer. pp. 389-414.
21. Bibby M (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. European Journal of Cancer 40: 852-857.
22. Avella DM, Li G, Schell TD, Liu D, Zhang SS, et al. (2012) Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology 55: 141-152.
23. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. (2011) Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53: 483-492.
24. Blow N (2009) In vivo molecular imaging: the inside job. Nature Methods 6: 465-469.
25. Ma X, Tian J, Yang X, Qin C, Zhu S, et al. (2011) Research on liver tumor proliferation and angiogenesis based on multi-modality molecular imaging. Acta Biophys Sin 27: 355-364.
26. Zhu S, Tian J, Yan G, Qin C, Feng J (2009) Cone beam micro-CT system for small animal imaging and performance evaluation. Journal of Biomedical Imaging DOI:10.1155/2009/960573.
27. Tian J, Xue J, Dai Y, Chen J, Zheng J (2008) A novel software platform for medical image processing and analyzing. Information Technology in Biomedicine, IEEE Transactions on 12: 800-812.
28. Xue Z, Ma X, Zhang Q, Wu P, Yang X, et al. (2013) Adaptive regularized method based on homotopy for sparse fluorescence tomography. Appl Opt 52: 2374-2384.
29. Hoffman RM (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359.
30. Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews 17: 279-284. (Pubitemid 29210167)
31. Hu H, Liu J, Yao L, Yin J, Su N, et al. Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model. Oncol Rep 27: 1937-1943.
32. Virostko J, Powers AC, Jansen ED (2007) Validation of luminescent source reconstruction using single-view spectrally resolved bioluminescence images. Appl Opt 46: 2540-2547. (Pubitemid 46918398)
33. Cheong SJ, Lee CM, Kim EM, Uhm TB, Jeong HJ, et al. (2011) Evaluation of the therapeutic efficacy of a VEGFR2-blocking antibody using sodium-iodide symporter molecular imaging in a tumor xenograft model. Nucl Med Biol 38: 93-101.
34. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, et al. (2000) Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (New York, NY) 2: 491.
35. Xibo M, Zhaofei L, Xin Y, Qiujuan G, Shouping Z, et al. (2011) Dual-modality Monitoring of Tumor Response to Cyclophosphamide Therapy in Mice with Bioluminescence Imaging and Small-animal Positron Emission Tomography. Molecular imaging 10: 278-283.
36. Han D, Yang X, Liu K, Qin C, Zhang B, et al. (2011) Efficient reconstruction method for L1 regularization in fluorescence molecular tomography. Appl Opt 49: 6930-6937.
37. Han D, Tian J, Zhu S, Feng J, Qin C, et al. (2011) A fast reconstruction algorithm for fluorescence molecular tomography with sparsity regularization. Opt Express 18: 8630-8646.